- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
GE introduces new PET/CT
Discovery PET/CT 600 debuted at the RSNA meeting, taking a midtier position in GE Healthcare’s family of hybrid devices.
Discovery PET/CT 600 debuted at the RSNA meeting, taking a midtier position in GE Healthcare’s family of hybrid devices. Discovery PET/CT 600 uses an infrared tracking camera and reflective marker to measure a patient’s respiratory pattern and range of motion that can complicate imaging and lead to problems in evaluating patients for radiation therapy. The real-time position-management technology, developed by Varian Medical Systems, was integrated into the GE device through a partnership between the two firms. Synchronizing the scan with respiration requires substantial processing power, according to GE. The company met the challenge through a collaboration with IBM, which provided its BladeCenter server technology for use in the PET/CT.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
